Updated

Twist Bioscience has announced a partnership with Eli Lilly through TuneLab, expanding the company's exposure to AI-driven drug discovery. The collaboration positions Twist to benefit from the broader convergence of synthetic biology and artificial intelligence in pharmaceutical development. The partnership underscores growing industry momentum toward leveraging machine learning and AI tools to accelerate the drug discovery pipeline and reduce time-to-market for new therapeutics.